1. 3110 Safety and clinical activity of avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with advanced, unresectable mesothelioma: A phase IB trial. (September 2015) Authors: Hassan, R.; Thomas, A.; Patel, M.; Nemunaitis, J.; Bennouna, J.; Powderly, J.; Taylor, M.; Cuillerot, J.M.; Heydebreck, A. Von; Gulley, J.L. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S639 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 3334 Durable complete responses (CR) in patients (pts) with stage IIIB-IV melanoma treated with talimogene laherparepvec (T-VEC) in OPTiM. (September 2015) Authors: Andtbacka, R.H.I.; Kaufman, H.; Collichio, F.; Amatruda, T.; Nemunaitis, J.; Chesney, J.; Puzanov, I.; Harrington, K.; Zhang, Y.; Chen, L.; Shilkrut, M.; Ross, M. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S676 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 366 Effects of rifampin, a strong metabolic enzyme inducer, on the pharmacokinetics (PK) of alisertib (MLN8237), an investigational Aurora A kinase inhibitor (AAKi), in patients with advanced solid tumors or lymphomas. (September 2015) Authors: Zhou, X.; Pant, S.; Sarantopoulos, J.; Patel, M.; Nemunaitis, J.; Lockhart, A.C.; Zhang, B.; Bargfrede, M.; Muehler, A.; Venkatakrishnan, K. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S76 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. 367 Effects of alisertib (MLN8237), an investigational Aurora A kinase inhibitor (AAKi), on the QTc interval in patients (pts) with advanced malignancies. (September 2015) Authors: Zhou, X.; Nemunaitis, J.; Pant, S.; Bauer, T.M.; Patel, M.; Sarantopoulos, J.; Lockhart, A.C.; Goodman, D.; Zhang, B.; Ullmann, C. Dansky; Mould, D.R.; Venkatakrishnan, K. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S76 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. A phase III study of belagenpumatucel-L, an allogeneic tumour cell vaccine, as maintenance therapy for non-small cell lung cancer. Issue 16 (November 2015) Authors: Giaccone, G.; Bazhenova, L.A.; Nemunaitis, J.; Tan, M.; Juhász, E.; Ramlau, R.; van den Heuvel, M.M.; Lal, R.; Kloecker, G.H; Eaton, K.D.; Chu, Q.; Dunlop, D.J.; Jain, M.; Garon, E.B.; Davis, C.S.; Carrier, E.; Moses, S.C.; Shawler, D.L.; Fakhrai, H. Journal: European journal of cancer Issue: Volume 51:Issue 16(2015:Nov.) Page Start: 2321 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Pharmacokinetics (PK) of alisertib (MLN8237) in adult patients (pts) with advanced solid tumors or relapsed/refractory lymphoma with varying degrees of hepatic function. (December 2016) Authors: Zhou, X.; Lockhart, A.C.; Fu, S.; Nemunaitis, J.; Sarantopoulos, J.; Smith, D.; Muehler, A.; Rangachari, L.; Bargfrede, M.; Huebner, D.; Venkatakrishnan, K. Journal: European journal of cancer Issue: Volume 69(2016)supplement 1 Page Start: S115 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗